An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 22 Aug 2018
Price : $35 *
At a glance
- Drugs Elotuzumab (Primary) ; Nivolumab (Primary) ; Pomalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 10 Aug 2018 Planned initiation date changed from 1 Jul 2017 to 1 Dec 2018.
- 10 Aug 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 09 Feb 2018 Planned primary completion date changed from 31 Dec 2020 to 31 Dec 2021.